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Abstract
The increasing incidence of type 2 diabetes mellitus globally has increased the incidence of 
diabetes-associated complications such as nephropathy. DNA damage induced by oxidative 
stress might be one of the important mechanisms in the pathogenesis of diabetic complications. 
Two hundred Iranian individuals with the conditions of type 2 diabetes, diabetic nephropathy 
and nephropathy patients with no sign of diabetes and normal unaffected sex- and age-matched 
controls (50 in each group) were enrolled in the study. The background and the net levels of 
micronucleus (MN) formation as well as other cellular damages induced after in vitro treatment 
with 25 µg/ml of bleomycin (BLM) were evaluated using cytokinesis block MNs cytome assay 
(CBMN cyt) in peripheral blood lymphocytes. The background and net BLM-induced levels of 
MNs were significantly higher in all patient groups compared with the control (P < 0.01, P < 0.001, 
respectively). The frequency of MNs was significantly higher in those patients with prior incidence 
of nephropathy than those without. A positive association was observed between basal and net 
MN frequency among study groups and also between net genetic damages and serum creatinine 
value and duration of diabetes. The rate of basal and net apoptosis was significantly higher in 
patients with hyperglycemia. Our results indicate that increased genomic instability expressed 
as MNs is associated with nephropathy in all pathological stages. Therefore, implementation of 
MN assay in clinical level may potentially enhance the quality of management of patients with 
diabetes and its complications such as nephropathy.
Introduction
Epidemic of diabetes mellitus is growing globally, most of all dia-
betes patients suffer from type 2 diabetes mellitus (T2DM) (1). 
Microvascular complications such as diabetic nephropathy (DN) 
caused by the progressive nature of the disease lead to increased 
morbidity and healthcare costs.
DN, also known as glomerulosclerosis, nodular diabetic, inter-
papillary glomerulonephritis or Kimmelstiel Wilson syndrome, is a 
progressive condition marked by deteriorating kidney function. Its 
clinical feature is characterised by albuminuria (>300 mg/day or 
>200 μg/min) and confirmed on at least two occasions 3–6 months 
apart, irreversible and permanent decrease in glomerular filtration 
rate (GFR) and arterial hypertension (2).
There are several risk factors for DN development, those that 
cannot be altered (age, genetic factors, and race) and those could 
be changed (hypertension, hyperglycemia, dyslipidemia and GFR 
(3). The severity of the pathology is categorised by GFR parameter. 
The early stages of kidney disease (Stages 2 and 3)  are generally 
asymptomatic but manifested by kidney damage, whereas more 
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advanced stages (Stages 4 and 5) need treatment of uremia and its 
complications, and finally, for end-stage renal disease (ESRD), renal 
replacement therapy is required (4).
To date the only biomarker remains acceptable for diagnostic 
purposes is albuminuria, although some growth factors are expected 
to replace albuminuria in future (5,6). It was reported that in addi-
tion to pathologies directly associated with renal dysfunction, the 
incidence of cardiovascular pathologies and different types of cancer 
as well as increased levels of genetic damage were significantly higher 
in patients with kidney disease (7–11). These patients with genomic 
instability may have defects in DNA repair processes (11,12). 
Significant inter-individual variability in DNA repair machinery 
reported in these patients may be associated with biological factors 
and lifestyle, as well as with polymorphisms in DNA repair genes 
(13,14). Oxidative stress is defined as an imbalance between the pro-
duction and elimination of reactive oxygen species (ROS). It has been 
proposed that increased oxidative stress is one of the main factors 
in the development of hyperglycemia and that hyperglycemia then 
stimulates the production of ROS in the body. It was also reported 
that the oxidation of DNA bases and sugar-phosphate–binding sites 
can be sources of DNA damage in diabetes and hyperglycemia (15). 
Excessive levels of damage in biomolecules such as DNA induced 
by ROS might contribute to the development of diabetes-associated 
metabolic complications (16). Significant inter-individual variability 
in DNA repair even reported in healthy individuals may make some 
patients more susceptible for these metabolic complications.
DNA damages, both spontaneous and induced, have been 
reported to be markedly increased in type 1 diabetes mellitus (17) 
and also elevated frequency of micronuclei (MNs) was observed in 
both pregnant women with type 1 diabetes mellitus and their suc-
cessive newborns (18). It was reported in another study that the 
overall frequency of DNA damage and cytotoxicity had been cor-
related with A1C in prediabetic individuals (19). Also increased MN 
frequency in ESRD and its association with duration of treatment 
among haemodialysis (HD) patients have been reported earlier 
(20,21). Consequently, MN formation has been validated to be a 
biomarker for environmental mutagenic and carcinogenic exposures 
and genomic instability testing uses extensively as an indicator of 
chromosomal damages.
The associations of diabetes and cancer and the elevated cancer 
risk in diabetic patients have been confirmed in some studies (22–
24). These collective evidences indicate that diabetes is a pathophysi-
ological state of oxidative stress and DNA damage that can lead 
to various types of mutation to cause aberrations in cells, thereby 
increasing the risk of cancer. Bonassi et al. have reported the prelimi-
nary evidences that MN frequency in peripheral blood lymphocytes 
would be predictive of cancer risk, suggesting that increased MN 
formation would be associated with early events in carcinogenesis 
(25).
Although some studies to date have evaluated DNA damages 
in diabetes (19,24,26–30), our literature review showed no studies 
have yet compared DNA damages expressed as MNs in different 
patient groups enrolled in our study. Different approaches have been 
adapted to detect the levels of genetic damages such as the sister 
chromatid exchanges (31), comet (32,33) and MN assays (34–36).
The cytokinesis block MN cytome (CBMN cyt) assay is a com-
prehensive technique frequently used for measuring DNA damage, 
spindle defects, cytostasis and cytotoxicity in different tissue types, 
including lymphocytes. In this technique, DNA damages expressed 
as MNs are scored specifically in once-divided binucleated cells 
arrested at cytokinesis. The MN is an indicator of chromosome 
breakage and/or whole chromosome loss is an established bio-
marker for genomic instability. The nucleoplasmic bridge (NPB) is 
a biomarker of DNA misrepair and/or telomere end fusions, and 
the nuclear bud (NBUD) is considered as a biomarker of elimina-
tion of amplified DNA and/or DNA repair complexes. These three 
biomarkers, i.e., MN, NPB and NBUD, are the end points evaluated 
with this technique. Cytostatic and cytotoxicity effects are meas-
ured via nuclear division index (NDI) considering the proportion of 
mono-, bi-, and multinucleated cells and necrotic and/or apoptotic 
cell ratios, respectively (37).
The ionizing radiation and radiomimetic agent bleomycin (BLM) 
are often used to test repair proficiency of cells and detect genomic 
instability. It has also been proposed that BLM sensitivity can be 
used as a biomarker for assessing risk of mutagen sensitivity. In 
exposure effect studies, lymphocytes are excellent available biologi-
cal systems with a relatively long lifespan that accumulate DNA 
damages (37,38).
The aim of the present study mainly was to evaluate the back-
ground and/or induced level of MN in type 2 diabetes, DN and 
nephropathy with no signs of hyperglycemia compared with the 
matched normal control in order to study its possible association 
with nephropathy complications in diabetic patients.
Materials and methods
Study population
The study was carried out as a case control study in a group of 
200 Iranian individuals who were resident of Tehran (capital of Iran; 
50 type 2 diabetes, 50 DN, 50 nephropathy with no hyperglyce-
mic symptoms and 50 unaffected sex- and age-matched controls). 
Patients with nephropathy complications were assigned to differ-
ent stages of the pathology according to their GFR; among them, 
11 were in the early stages (Stages 2–3; GFR > 30–89 mL/min) in 
both DN and nephropathy groups. Fifteen and 11 individuals were 
in the late stages (Stages 4–5, GFR > 15–29 mL/min) and 24 and 28 
patients underwent HD treatment in DN and nephropathy groups, 
respectively. General and lifestyle information of the patients also 
family pedigrees were recorded. None of the individuals participated 
in the study was heavy or moderate smoker (more than 20 pack in 
a year). Since some of the patients in all three test groups were con-
sidered light smokers (0 < pack-years ≤ 20), 12 in the control group 
were selected as light smokers. The protocol was approved by the 
Ethical Committee of the National Institute of Genetic Engineering 
and Biotechnology (NIGEB), Iran. Patients and controls signed a 
written informed consent letter before enrolment. Table  1 shows 
clinical and analytical data for test and control groups. The patients 
with type 2 diabetes and nephropathic patients who had an esti-
mated GFR of 22.5 mL/min received conventional treatment. The 
HD was done three times a week for ESRD group. Patients with bac-
terial infections, oncological disease, hepatitis C or B or HIV posi-
tive, hepatic insufficiency or immunosuppressive therapy, antibiotics 
uptake and exposed to ionizing radiation at least 1 month prior to 
sampling were excluded. Healthy volunteers who met the inclusion 
criteria served as control subjects. The relevant data regarding the 
clinical reports from all subjects was recorded.
Cell culturing, BLM treatment and CBMN cyt assay
Blood samples were drawn by venipuncture into sodium–heparin 
vacutainers and processed within 3 h after retrieved at the hospital. 
For each individual, four lymphocyte cultures were set up by adding 
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0.5 mL of whole blood into 4.5 mL of RPMI 1640 medium supple-
mented with 15% fetal bovine serum, 1% antibiotics (100 IU/mL 
penicillin and 100 µg/mL streptomycin) and 0.15 mL phytohaemag-
glutinin were also added to the cultures (all provided by Gibco Life 
Technologies, Paisley, UK). Two cultures were treated with BLM at 
a dose of 25 µg/mL final concentration, 24 h prior to harvesting of 
the cells. The other two were used to assess the background lev-
els of MN. The duration for BLM treatment and optimal dose was 
earlier established in a set of experiments on human lymphocytes. 
To roll-out the treatment cytotoxicity to the peripheral lymphocytes, 
cell viability was estimated on the basis of trypan blue (always the 
number of dye excluding cells was greater than 90% in each culture; 
data not shown).
Lymphocytes (BLM treated and untreated) were cultured at 37°C 
for 72 h. After 44 h, cytochalasin B (GIBCO, 6 μg/mL) was added to 
the culture to arrest cells at cytokinesis. At 72 h of incubation, cul-
tures were harvested by centrifugation at 120g for 8 min followed by 
a brief hypotonic treatment (2–3 min in 0.075 M KCl at 48°C). The 
cells were centrifuged, then fixed and washed in methanol/acetic acid 
(3:1 v/v) solution three times. The resulting cells were resuspended 
and dropped onto clean slides. Slides were coded and stained with 
10% of Giemsa (Merck, Darmstadt, Germany) in phosphate buffer 
(pH 6.8) for 5 min.
Scoring and data evaluation
The scoring criteria established by Fenech (39) were used for CBMN 
Cyt assay analysis. To determine the frequency of CBMN assay end 
points (MNs, NPB and NBUDs) as well as apoptosis and necrosis, a 
total of 1000 binucleated cells with well-preserved cytoplasm were 
blind scored on coded slides. In addition, a total of 500 lymphocytes 
were scored to determine the percentage of cells with one, two, or 
more nuclei in order to calculate the NDI. To better visualise the 
response to BLM treatment, a net nuclear aberrations value was 
estimated by calculating the difference between nuclear aberrations 
after 25 µg/mL of BLM treatment and the background nuclear aber-
rations values.
Statistical analyses
Statistical computations were performed using the SPSS version 16.0 
(SPSS, Chicago, IL, USA). The comparison of frequencies of nuclear 
aberrations between the patient groups and the control group was 
carried out using an analysis of variance test. A Student’s t-test was 
performed for comparisons between two groups. For all analyses, 
differences were accepted as statistical significant at P < 0.05. Linear 
regressions were performed to establish the correlation between 
basal and BLM-induced MN. The general linear model was per-
formed with the net BNMN parameter taking into account the con-
founding factors. Numerical data are presented as mean ± SD.
Results
The demographic characteristics of the study 
population
Table  1 summarises the demographic, clinical and biochemical 
data for the different groups of patients and control. The data are 
presented as mean ± SD. Except in nephropathy groups where the 
frequency of male gender was higher (P < 0.05), no other signifi-
cant differences were observed in terms of age and gender among 
other patients and controls. The mean age of cases (DN, type 2 
diabetes and nephropathy groups) were 60.10 ± 11.23, 58.2 ± 9.8, 
58.4 ± 10.9, respectively compared with the control that was 
57.11 ± 9.97.
Body mass index (BMI) was significantly higher in diabetic group 
compared with other study groups (P  <  0.05). The differences in 
the routine biochemical parameters were as expected: creatinine and 
urea were higher in nephropathy complication groups both with and 
without diabetes when compared with other groups (P  <  0.001). 
Glycated haemoglobin and fasting blood glucose was higher in both 
diabetic and DN compared with nephropathy and control groups 
(P < 0.001). The duration of diabetes was 10 to 20 years in type 2 
diabetes group.
CBMN assay in the studied populations
The background and BLM-induced MN frequency, as well as 
NBUDs and NPBs in binucleated peripheral blood lymphocytes 
(PBL) and micronucleated cell frequency in different tests and 
control groups, are summarised in Table 2. The background fre-
quency of MNs was significantly higher in all three test groups 
(DN, nephropathy and type 2 diabetes) compared with the con-
trol, whereas the value of this frequency was significantly higher 
Table 1. Clinical and analytical data for DN, type 2 diabetic (T2DM), nephropathy patients and controls
Diabetic nephropathy Diabetes Nephropathy Control
Sample size 50 50 50 50
Age mean ± SD 60.10 ± 11.23 58.2 ± 9.8 58.4 ± 10.9 57.11 ± 9.97
Sex (M/F) 32 (M) 22 (M) 35 (M) 25 (M)
18 (F) 28 (F) 15 (F) 25 (F)
BMI (kg/m2) 25.9 ± 3.4 28 ± 0.4 25.95 ± 0.37 26.32 ± 0.96
eGFR (mL/min) <15 (N: 24) 106 ± 20.2 <15 (N: 28) 114.1 ± 28.2
15–29(N: 15) 15–29 (N: 11)
30–89 (N: 11) 30–89 (N: 11)
Fasting plasma glucose in mg/dL ± SD 240 ± 40.8 230 ± 32.5 90 ± 9.3 89 ± 9.8
Glycated haemoglobin ± SD 7.5 ± 1.8 9.22 ± 1.76 5 ± 0.7 5 ± 0.5
Serum creatinine (mg/dL) 10.6 ± 2.7 0.8 ± 0.2 9.1 ± 2.3 0.8 ± 0.2
Duration of diabetes (range) 1 month–20 years 10–20 years – –
Smoking intensity
 Light (0 < pack-years ≤ 20) 10 11 6 12
 Moderate (20 < pack-years ≤ 40) – – – –
 Heavy (>40 pack-years) – – – –
SD: standard deviation, BMI: body mass index, eGFR: estimated glomerular filtration rate.
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in both groups accompanied with nephropathy complications, DN 
and nephropathy, independent of the GFR status (P < 0.01). Similar 
trend of MN formation was observed when the frequency of MNs 
was analysed per 1000 binucleated cells following BLM treatment. 
This can be better visualised when the net MN frequency is calcu-
lated (36.08 ± 8.03, 43.7 ± 6.6, 42.18 ± 5.51, 24.76 ± 3.30 for type 
2 diabetes, DN, nephropathy and control groups, respectively; 
P  <  0.001). As shown in Figure  1, when nephropathy and DN 
patients were stratified according to the pathological stage of the 
disease, no significant difference was observed between the early 
and late stage groups (P > 0.05). However, ESRD patients who 
underwent HD showed the highest level of net MN frequency (P 
> 0.001).
As seen in Figures 2 and 3, among the different confounding fac-
tors taken into account (Table 1), duration of diabetes in diabetic 
groups and serum creatinine value in nephropathy groups were 
correlated with MN frequency rate (R2 = 0.98, P <0.01, R2 = 0.63, 
P < 0.05, respectively).
Our data showed that the background, BLM-induced and net 
frequency of both NBUDs and NPBs were significantly higher than 
control in all three test groups (P < 0.001; Table 2). Moreover, the 
net frequency of NBUDs was also significantly higher in type 2 
diabetic group compared with other patients groups (P  < 0.001; 
Table 2).
The rate of apoptosis in both hyperglycemic test groups, type 2 
diabetes and DN, was significantly higher than other patients, groups 
(P < 0.001), whereas no statistically significant difference was shown 
between net necrosis rate among all three tests and control groups (P 
> 0.05; Table 2, Figure 4).
Discussion
There are some moderate-to-severe secondary complications for dia-
betes that early diagnosis and treatment of them is essential to mini-
mise further taxes. Nephropathy is considered as one of the most 
important complications of diabetes.
It was reported that oxidative stress can cause DNA damage in 
patients with diabetes mellitus (19,26,27). Also previous cytogenetic 
Figure  1. Net MN prevalence in different stages of nephropathy based on 
GFR compared with the normal control group. Stages 2–3; GFR > 30–89 mL/
min; Stages 4–5, GFR > 15–29 mL/min; ESRD; and underwent HD treatment.
Table 2. Background and BLM-induced cytogenetic and cytotoxicity parameters in the studied population [type 2 diabetic (T2DM), DN, 
nephropathy patients and controls (C)]
T2DM (mean ± SD) DN (mean ± SD) Nephropathy (mean ± SD) Control (mean ± SD)
Cytogenetic
 Background MN 8.16 ± 1.47a* 15.O8 ± 5.03*a/**c 15.12 ± 4.64a*/**c 5.82 ± 2.17*b
 BLM-induced MN 44.86 ± 8.51*a 58.58 ± 6.06*a/**c 55.4 ± 5.49a*/**c 30.58 ± 4.36*b
 Net MN 36.08 ± 8.03*a 43.7 ± 6.6*a/**c 42.18 ± 5.5*a/**c 24.76 ± 3.30*b
 Background micronucleated cell 8.08 ± 1.44*a 12.1 ± 2.45*a/**c 12.4 ± 2.28*a/**c 5.64 ± 2.02*b
 BLM-induced Micronucleated cell 44.18 ± 8.22*a 57.32 ± 5.85*a/**c 54.78 ± 5.83*a/**c 30.08 ± 4.21*b
 Net micronucleated cell 36.02 ± 7.79*a 45.3 ± 5.35*a/**c 40.28 ± 6.15*a/**c 24.44 ± 3.21*b
 Background NBUD frequency 1.56 ± 0.83**a 2.52 ± 1.4*a 2.14 ± 1.26*a 1 ± 0.82**b
 BLM-induced NBUD frequency 4.8 ± 1.14*a 5 ± 0.77*a 4.6 ± 0.93*a 2.5 ± 1.17**b
 Net NBUD frequency 3.64 ± 1.16*a/*d 2.52 ± 1.08*a 2.46 ± 1.16*a 1.5 ± 0.92*b
 Background NPB frequency 5.4 ± 2.18*a 5.64 ± 1.89*a 5.58 ± 2.19*a 1.84 ± 1.04*b
 BLM-induced NPB frequency 15.06 ± 2.01*a 14.38 ± 2.12*a 14.02 ± 1.72*a 4 ± 1.63*b
 Net NPB frequency 9.74 ± 2.79*a 8.74 ± 2.91*a 8.4 ± 2.69*a 2.28 ± 1.57*b
Cytostatic
 Background NDI 1.93 ± 0.3 1.9 ± 0.31 1.95 ± 0.29 1.9 ± 0.31
 BLM-induced NDI 1.83 ± 0.17 1.97 ± 0.16 1.94 ± 0.14 1.96 ± 0.17
Cytotoxicity
 Background apoptosis 7.78 ± 1.76**a/*e 8.06 ± 2.02**a/*e 5.04 ± 1.46 5 ± 1.13
 BLM-induced apoptosis frequency 12.32 ± 1.22**a/*e 12 ± 2.03**a/*e 7.64 ± 1.68 7.08 ± 1.7
 Net apoptosis frequency 4.42 ± 2.13**a/*e 4.06 ± 2.61**a/*e 2.68 ± 2.01 2.04 ± 1.83
 Background necrosis frequency 4.34 ± 1.35 4.06 ± 1.34 3.86 ± 1.34 3 ± 1.48
 BLM-induced necrosis frequency 7.98 ± 2.24 8 ± 1.87 7.68 ± 1.55 7.2 ± 1.6
 Net necrosis frequency 3.84 ± 1.83 3.94 ± 1.47 3.82 ± 1.8 4 ± 2.4
ANOVA: analysis of variance. NDI = (Mononucleated cells + 2 × binucleated cells + 3 × trinucleated cells + 4 × tetranucleated cells)/total number of cells.
at-Test with control group as reference.
bANOVA test: C versus DN, nephropathy and T2DM groups.
cANOVA test: DN and nephropathy versus T2DM and C groups.
d ANOVA test: T2DM versus DN, nephropathy and C groups.
e ANOVA test: T2DM and DN versus nephropathy and C groups.
*P≤0.001; **P≤0.01
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effect studies on chronic kidney disease and treatment modes have 
compared patients with moderate-to-severe chronic kidney insuffi-
ciency (20,32,34–36,40–43).
MNs in PBL (34–36,40) and buccal epithelial cells (20), chromo-
some aberrations, sister chromatid exchanges (41) and DNA strand 
breaks (comet assay) (32,34,41–43) were the biomarkers used in these 
studies carried out on adults and children (44). CBMN assay has been 
applied to examine the effect of variety of factors such as genetics, 
lifestyle, environmental and dietary on chromosomal stability and 
mitotic function (45–47). Although the frequency of MNs alone has 
been considered as a good indicator of genetic instability, an individu-
al’s instability is better determined when sampled cells are challenged 
with the defined dose of a standard genotoxic agent, such as ionizing 
radiation or a radio mimetic agent like BLM. Since each individual 
reacts in a different way to external stimulation by activating a series 
of biological responses such as DNA repair mechanisms, sensitivity to 
BLM can be considered as an individual susceptibility measurement 
to chemical and physical insults. Therefore, chromosome sensitivity 
to BLM measured by the MN assay is considered as an important 
biomarker of genomic instability and cancer predisposition (45,48).
Our data demonstrated that the frequency of DNA damage 
expressed as nuclear aberrations was significantly higher in the 
patient groups compared with normal controls. We studied different 
CBMN assay end points (Table 2) and the frequency of MNs was 
chosen as a biomarker of effects. This biomarker has great biological 
relevance since MNs represent fixed genetic damage resulting from 
both aneugenic and clastogenic mechanisms (39), and it is considered 
as a good surrogate marker of cancer risk (17). Our results indicated 
that in type 2 diabetes, the frequency of MNs increased significantly 
with the duration of diabetes. It could be due to the increasing sus-
ceptibility of the patients to DNA damage with the increase in the 
duration of diabetes. However, the frequency of nuclear aberrations 
was not dependent on the age of the patients. No significant varia-
tion was also observed in the frequency of aberrations between those 
with a family history of T2DM and those without, implying that the 
aberrations are due to the damage caused by diabetes progression.
Our data showed the higher frequency of MNs in nephropathy 
patients both with/without diabetes compared with the diabetic 
ones with no signs of nephropathy complications. In other words, 
nephropathy complications caused more genetic damages regard-
less of hyperglycemia. There are evidences showing impaired DNA 
repair and increased chromosome damage in patients with kidney 
disease. This might be caused by the uraemic state as well as by 
chronic inflammation linked to increased formation of reactive oxy-
gen and nitrogen species (denoted RONS) (21,49). Increased RONS 
may lead to DNA strand breaks, point mutations and aberrant DNA 
cross-linking, thereby causing genomic instability (50). It also has 
been postulated to be an important risk factor for cardiovascular 
disorders and the development of cancer (31) and could be responsi-
ble for genomic instability in patients with kidney disease.
Our results showed that there was no significant difference in 
MN frequency between Stages 2 and 5 of the pathology regarding 
the GFR parameter, but those ESRD patients who underwent HD 
treatment had significantly higher net genetic damage than those in 
the other stages. This might indicate that genomic instability is an 
individual characteristic not affected by the worsening of the pathol-
ogy and that higher MN frequency can be attributed to a lower 
DNA repair capacity of nephropathy patients under HD treatment. 
Our study was in line with other studies that defined that structural 
DNA damage, such as single- and double-strand breaks and alkali-
labile sites, was significantly increased in lymphocytes of patients 
under dialysis (20,41,51). It was stated that since DNA repair capac-
ity is reduced by prolonged HD therapy, these types of DNA dam-
ages that are theoretically repairable could not be repaired properly 
and may have serious consequences, such as premature ageing (52), 
atherosclerosis (53) and cancer predisposition.
Although it is assumed that nephropathy patients have increased 
levels of genetic damage, there is uncertainty on the origin of such 
damage. There are some points of view that are listed as follows: (i) 
biological implications of renal disease and uremic milieu that have 
genotoxic potential on the integrity of DNA (54); (ii) the modality 
Figure 2. Linear regression between creatinine value and MN frequency in 
nephropathy patients with/without diabetes.
Figure 3. Linear regression between duration of diabetes and mean of MN 
frequency.
Figure 4. Cytotoxicity parameters in the studied populations [type 2 diabetic 
(T2DM), diabetic nephropathy (DN), nephropathy patients and controls (C)]. 
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and duration of the uremia treatment may also influence the degree 
of DNA damage or the mechanisms of repair (21,34); (iii) different 
individual predisposition to genomic instability, due to existence of 
genetic polymorphisms in genes, such as DNA repair genes, involved 
in the maintenance of the genome integrity.(55) Our results some-
how supported this latter view that a genetic predisposition exists in 
nephropathy patients both diabetic and non-diabetic, at least in part, 
is responsible for the incidence of the pathology. This view was sup-
ported by the existence of both increased levels of genetic damage 
and increased sensitivity to BLM treatment in patients, regardless of 
different stages of the pathology and also by the good correlation 
observed between background and net genetic damages.
In our study, higher BMI and higher frequency of NBUD and apop-
tosis were observed in diabetic patients. These data were somehow in 
line with the study reported by Donmez-Altuntas recently (56), where a 
positive correlation was found between BMI and frequency of BUDs in 
a group of obese, overweight and normal weight subjects. The NBUD 
is considered as a biomarker of gene amplification by a mechanism in 
which a nucleus eliminates amplified DNA and DNA repair complexes 
(39). Inflammation and elevated levels of inflammatory markers cor-
relate with the risk of variety of complications such as insulin resist-
ance, cardiovascular disease, diabetes, dislipidemia and atherosclerosis 
(57). The diabetic patients in our study suffered from hyperglycemia 
for more than 10 years, therefore they might be chronically exposed 
to inflammatory factors due to hyperglycemic situation. It was previ-
ously reported that chronic inflammation is associated with induction 
of DNA damage. All DNA damages are subjected to repair by cellu-
lar repair systems, therefore, complexes formed due to repair of DNA 
damage might be eliminated as NBUDs from the nucleus (58).
Association of genetic damage with routine biochemical param-
eters such as blood urea nitrogen, creatinine and ferritin levels was 
shown in previous studies (20,34,35). Despite the opinion that the 
level of background damage is significantly associated with the 
degree of renal failure (36), such an association was not observed in 
our study. Our results are somehow in line with the research done by 
Sandoval et al. in chronic renal failure patients that they reported no 
association between genomic instability and neither pathologic stages 
nor cratinine level and GFR parameter (29). In our study, no associa-
tion was found between frequency of MNs and GFR parameter but 
that association was somehow found with serum creatinine levels. 
Although patients with nephropathy present higher level of net MN 
frequency in both diabetic and non-diabetic groups, important inter-
individual variations were found for both control and patient groups. 
The variability observed before the BLM treatment (background 
damage) was correlated with the level of damage observed after treat-
ment in all the test groups. The MN frequency showed proportional 
increase in the values of genetic damage after treatment with BLM.
These results suggest that the MN frequency measured in lym-
phocytes challenged with in vitro BLM treatment could be con-
sidered as a biomarker to different pathologies, including DN. 
Limitations in our study necessitate consideration. First, we used a 
hospital-based case recruitment system, therefore, our study is not 
population based and selection bias may have occurred. Second, we 
were not able to measure environmental exposure quantitatively. 
Environmental exposure was based on a self-reported ever or never 
response, and therefore, recall and reporting bias is a possibility.
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